ProNAi Therapeutics Inc. (NASDAQ:DNAI) shares were down 0.5% on Friday . The stock traded as low as $2.01 and last traded at $2.06, with a volume of 362,203 shares traded. The stock had previously closed at $2.05.

Several research analysts have recently weighed in on DNAI shares. Zacks Investment Research downgraded ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of ProNAi Therapeutics in a research report on Friday, May 27th. Jefferies Group reiterated a “buy” rating on shares of ProNAi Therapeutics in a research report on Sunday, May 29th. Finally, SunTrust Banks Inc. cut ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $4.00 in a research report on Monday, June 6th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. ProNAi Therapeutics presently has an average rating of “Hold” and a consensus price target of $17.35.

The stock has a 50-day moving average price of $3.23 and a 200-day moving average price of $6.60. The stock’s market cap is $62.16 million.

ProNAi Therapeutics (NASDAQ:DNAI) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. Analysts expect that ProNAi Therapeutics Inc. will post ($1.33) earnings per share for the current fiscal year.

An institutional investor recently raised its position in ProNAi Therapeutics stock. Greenleaf Trust raised its stake in ProNAi Therapeutics Inc. (NASDAQ:DNAI) by 96.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 190,812 shares of the company’s stock after buying an additional 93,812 shares during the period. Greenleaf Trust owned about 0.63% of ProNAi Therapeutics worth $2,870,000 as of its most recent SEC filing.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.